APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vector-Based RNAi

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vector-Based RNAi Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025190 pages

Choose your research edition.

Industry ResearchVector-Based RNAi Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Vector-Based RNAi Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Vector-Based RNAi Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vector-Based RNAi Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Vector-Based RNAi Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vector-Based RNAi market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vector-Based RNAi include Alnylam Pharmaceuticals, Arcturus Therapeutics, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Ionis Pharmaceutical, Phio Pharmaceutical, Qiagen NV, Quark Pharmaceuticals and Silence Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vector-Based RNAi market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vector-Based RNAi and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vector-Based RNAi sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vector-Based RNAi market size, projected growth trends, production technologies, key applications, and end-use industries.

Vector-Based RNAi Segment by Company

Alnylam Pharmaceuticals

Arcturus Therapeutics

Arrowhead Pharmaceuticals

Dicerna Pharmaceuticals

Ionis Pharmaceutical

Phio Pharmaceutical

Qiagen NV

Quark Pharmaceuticals

Silence Therapeutics

Merck & Co.

Thermo Fisher Scientific

Vector-Based RNAi Segment by Type

Custom siRNA Construction

siRNA Vectors

siRNA Design

Vector-Based RNAi Segment by Application

Hospitals

Speciality Clinics

Vector-Based RNAi Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vector-Based RNAi market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vector-Based RNAi and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vector-Based RNAi.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vector-Based RNAi market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vector-Based RNAi manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vector-Based RNAi in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vector-Based RNAi in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vector-Based RNAi Industry Trends Table 2. Vector-Based RNAi Industry Drivers Table 3. Vector-Based RNAi Industry Opportunities and Challenges Table 4. Vector-Based RNAi Industry Restraints Table 5. Global Vector-Based RNAi Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vector-Based RNAi Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vector-Based RNAi Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Vector-Based RNAi Sales Market Share by Manufacturers Table 9. Global Vector-Based RNAi Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vector-Based RNAi Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vector-Based RNAi Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vector-Based RNAi Manufacturers, Product Type & Application Table 13. Global Vector-Based RNAi Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vector-Based RNAi by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Custom siRNA Construction Table 17. Major Manufacturers of siRNA Vectors Table 18. Major Manufacturers of siRNA Design Table 19. Global Vector-Based RNAi Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Vector-Based RNAi Sales by Type (2021-2026) & (K Units) Table 21. Global Vector-Based RNAi Sales by Type (2027-2032) & (K Units) Table 22. Global Vector-Based RNAi Sales Market Share by Type (2021-2026) Table 23. Global Vector-Based RNAi Sales Market Share by Type (2027-2032) Table 24. Global Vector-Based RNAi Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Vector-Based RNAi Revenue by Type (2021-2026) & (K Units) Table 26. Global Vector-Based RNAi Revenue by Type (2027-2032) & (K Units) Table 27. Global Vector-Based RNAi Revenue Market Share by Type (2021-2026) Table 28. Global Vector-Based RNAi Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Speciality Clinics Table 31. Global Vector-Based RNAi Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Vector-Based RNAi Sales by Application (2021-2026) & (K Units) Table 33. Global Vector-Based RNAi Sales by Application (2027-2032) & (K Units) Table 34. Global Vector-Based RNAi Sales Market Share by Application (2021-2026) Table 35. Global Vector-Based RNAi Sales Market Share by Application (2027-2032) Table 36. Global Vector-Based RNAi Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Vector-Based RNAi Revenue by Application (2021-2026) & (K Units) Table 38. Global Vector-Based RNAi Revenue by Application (2027-2032) & (K Units) Table 39. Global Vector-Based RNAi Revenue Market Share by Application (2021-2026) Table 40. Global Vector-Based RNAi Revenue Market Share by Application (2027-2032) Table 41. Global Vector-Based RNAi Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Vector-Based RNAi Sales by Region (2021-2026) & (K Units) Table 43. Global Vector-Based RNAi Sales Market Share by Region (2021-2026) Table 44. Global Vector-Based RNAi Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Vector-Based RNAi Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Vector-Based RNAi Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 48. North America Vector-Based RNAi Sales by Country (2027-2032) & (K Units) Table 49. Europe Vector-Based RNAi Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 51. Europe Vector-Based RNAi Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Vector-Based RNAi Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Vector-Based RNAi Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Vector-Based RNAi Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Vector-Based RNAi Sales by Country (2027-2032) & (K Units) Table 58. Global Vector-Based RNAi Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Vector-Based RNAi Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Vector-Based RNAi Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Vector-Based RNAi Revenue Market Share by Region (2021-2026) Table 62. Global Vector-Based RNAi Revenue Market Share by Region (2027-2032) Table 63. Alnylam Pharmaceuticals Company Information Table 64. Alnylam Pharmaceuticals Business Overview Table 65. Alnylam Pharmaceuticals Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolio Table 67. Alnylam Pharmaceuticals Recent Development Table 68. Arcturus Therapeutics Company Information Table 69. Arcturus Therapeutics Business Overview Table 70. Arcturus Therapeutics Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Arcturus Therapeutics Vector-Based RNAi Product Portfolio Table 72. Arcturus Therapeutics Recent Development Table 73. Arrowhead Pharmaceuticals Company Information Table 74. Arrowhead Pharmaceuticals Business Overview Table 75. Arrowhead Pharmaceuticals Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolio Table 77. Arrowhead Pharmaceuticals Recent Development Table 78. Dicerna Pharmaceuticals Company Information Table 79. Dicerna Pharmaceuticals Business Overview Table 80. Dicerna Pharmaceuticals Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolio Table 82. Dicerna Pharmaceuticals Recent Development Table 83. Ionis Pharmaceutical Company Information Table 84. Ionis Pharmaceutical Business Overview Table 85. Ionis Pharmaceutical Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Ionis Pharmaceutical Vector-Based RNAi Product Portfolio Table 87. Ionis Pharmaceutical Recent Development Table 88. Phio Pharmaceutical Company Information Table 89. Phio Pharmaceutical Business Overview Table 90. Phio Pharmaceutical Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Phio Pharmaceutical Vector-Based RNAi Product Portfolio Table 92. Phio Pharmaceutical Recent Development Table 93. Qiagen NV Company Information Table 94. Qiagen NV Business Overview Table 95. Qiagen NV Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Qiagen NV Vector-Based RNAi Product Portfolio Table 97. Qiagen NV Recent Development Table 98. Quark Pharmaceuticals Company Information Table 99. Quark Pharmaceuticals Business Overview Table 100. Quark Pharmaceuticals Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Quark Pharmaceuticals Vector-Based RNAi Product Portfolio Table 102. Quark Pharmaceuticals Recent Development Table 103. Silence Therapeutics Company Information Table 104. Silence Therapeutics Business Overview Table 105. Silence Therapeutics Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Silence Therapeutics Vector-Based RNAi Product Portfolio Table 107. Silence Therapeutics Recent Development Table 108. Merck & Co. Company Information Table 109. Merck & Co. Business Overview Table 110. Merck & Co. Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Merck & Co. Vector-Based RNAi Product Portfolio Table 112. Merck & Co. Recent Development Table 113. Thermo Fisher Scientific Company Information Table 114. Thermo Fisher Scientific Business Overview Table 115. Thermo Fisher Scientific Vector-Based RNAi Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Thermo Fisher Scientific Vector-Based RNAi Product Portfolio Table 117. Thermo Fisher Scientific Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Vector-Based RNAi Distributors List Table 121. Vector-Based RNAi Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Vector-Based RNAi Product Image Figure 2. Global Vector-Based RNAi Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vector-Based RNAi Market Size (2021-2032) & (US$ Million) Figure 4. Global Vector-Based RNAi Sales (2021-2032) & (K Units) Figure 5. Global Vector-Based RNAi Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Vector-Based RNAi Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Custom siRNA Construction Image Figure 9. siRNA Vectors Image Figure 10. siRNA Design Image Figure 11. Global Vector-Based RNAi Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Vector-Based RNAi Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Vector-Based RNAi Sales Market Share by Type (2021-2032) Figure 14. Global Vector-Based RNAi Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Vector-Based RNAi Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Vector-Based RNAi Revenue Market Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Speciality Clinics Image Figure 19. Global Vector-Based RNAi Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Vector-Based RNAi Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Vector-Based RNAi Sales Market Share by Application (2021-2032) Figure 22. Global Vector-Based RNAi Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Vector-Based RNAi Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Vector-Based RNAi Revenue Market Share by Application (2021-2032) Figure 25. North America Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Vector-Based RNAi Sales Market Share by Country (2021-2032) Figure 27. U.S. Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Vector-Based RNAi Sales Market Share by Country (2021-2032) Figure 32. Germany Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Vector-Based RNAi Sales Market Share by Country (2021-2032) Figure 39. China Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Vector-Based RNAi Sales Market Share by Country (2021-2032) Figure 47. Brazil Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Vector-Based RNAi Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Vector-Based RNAi Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Vector-Based RNAi Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Vector-Based RNAi Revenue (2021-2032) & (US$ Million) Figure 58. North America Vector-Based RNAi Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Vector-Based RNAi Revenue (2021-2032) & (US$ Million) Figure 60. Europe Vector-Based RNAi Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Vector-Based RNAi Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Vector-Based RNAi Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Vector-Based RNAi Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Vector-Based RNAi Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Vector-Based RNAi Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Vector-Based RNAi Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Custom siRNA Construction
  • siRNA Vectors
  • siRNA Design
Applications
  • Hospitals
  • Speciality Clinics
Companies covered
  • Alnylam Pharmaceuticals
  • Arcturus Therapeutics
  • Arrowhead Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Ionis Pharmaceutical
  • Phio Pharmaceutical
  • Qiagen NV
  • Quark Pharmaceuticals
  • Silence Therapeutics
  • Merck & Co.
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vector-Based RNAi Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vector-Based RNAi Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vector-Based RNAi Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vector-Based RNAi Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vector-Based RNAi Market Dynamics
  1. 2.1 Vector-Based RNAi Industry Trends
  2. 2.2 Vector-Based RNAi Industry Drivers
  3. 2.3 Vector-Based RNAi Industry Opportunities and Challenges
  4. 2.4 Vector-Based RNAi Industry Restraints
3 Vector-Based RNAi Market by Manufacturers
  1. 3.1 Global Vector-Based RNAi Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vector-Based RNAi Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vector-Based RNAi Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vector-Based RNAi Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vector-Based RNAi Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vector-Based RNAi Manufacturers, Product Type & Application
  7. 3.7 Global Vector-Based RNAi Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vector-Based RNAi Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vector-Based RNAi Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vector-Based RNAi Tier 1, Tier 2, and Tier 3
4 Vector-Based RNAi Market by Type
  1. 4.1 Vector-Based RNAi Type Introduction
  2. 4.1.1 Custom siRNA Construction
  3. 4.1.2 siRNA Vectors
  4. 4.1.3 siRNA Design
  5. 4.2 Global Vector-Based RNAi Sales by Type
  6. 4.2.1 Global Vector-Based RNAi Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Vector-Based RNAi Sales by Type (2021-2032)
  8. 4.2.3 Global Vector-Based RNAi Sales Market Share by Type (2021-2032)
  9. 4.3 Global Vector-Based RNAi Revenue by Type
  10. 4.3.1 Global Vector-Based RNAi Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Vector-Based RNAi Revenue by Type (2021-2032)
  12. 4.3.3 Global Vector-Based RNAi Revenue Market Share by Type (2021-2032)
5 Vector-Based RNAi Market by Application
  1. 5.1 Vector-Based RNAi Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Speciality Clinics
  4. 5.2 Global Vector-Based RNAi Sales by Application
  5. 5.2.1 Global Vector-Based RNAi Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vector-Based RNAi Sales by Application (2021-2032)
  7. 5.2.3 Global Vector-Based RNAi Sales Market Share by Application (2021-2032)
  8. 5.3 Global Vector-Based RNAi Revenue by Application
  9. 5.3.1 Global Vector-Based RNAi Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Vector-Based RNAi Revenue by Application (2021-2032)
  11. 5.3.3 Global Vector-Based RNAi Revenue Market Share by Application (2021-2032)
6 Global Vector-Based RNAi Sales by Region
  1. 6.1 Global Vector-Based RNAi Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vector-Based RNAi Sales by Region (2021-2032)
  3. 6.2.1 Global Vector-Based RNAi Sales by Region (2021-2026)
  4. 6.2.2 Global Vector-Based RNAi Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vector-Based RNAi Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vector-Based RNAi Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vector-Based RNAi Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vector-Based RNAi Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vector-Based RNAi Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vector-Based RNAi Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vector-Based RNAi Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vector-Based RNAi Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vector-Based RNAi Revenue by Region
  1. 7.1 Global Vector-Based RNAi Revenue by Region
  2. 7.1.1 Global Vector-Based RNAi Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vector-Based RNAi Revenue by Region (2021-2026)
  4. 7.1.3 Global Vector-Based RNAi Revenue by Region (2027-2032)
  5. 7.1.4 Global Vector-Based RNAi Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vector-Based RNAi Revenue (2021-2032)
  8. 7.2.2 North America Vector-Based RNAi Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vector-Based RNAi Revenue (2021-2032)
  11. 7.3.2 Europe Vector-Based RNAi Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vector-Based RNAi Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vector-Based RNAi Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vector-Based RNAi Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vector-Based RNAi Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Alnylam Pharmaceuticals
  2. 8.1.1 Alnylam Pharmaceuticals Company Information
  3. 8.1.2 Alnylam Pharmaceuticals Business Overview
  4. 8.1.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolio
  6. 8.1.5 Alnylam Pharmaceuticals Recent Developments
  7. 8.2 Arcturus Therapeutics
  8. 8.2.1 Arcturus Therapeutics Company Information
  9. 8.2.2 Arcturus Therapeutics Business Overview
  10. 8.2.3 Arcturus Therapeutics Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Arcturus Therapeutics Vector-Based RNAi Product Portfolio
  12. 8.2.5 Arcturus Therapeutics Recent Developments
  13. 8.3 Arrowhead Pharmaceuticals
  14. 8.3.1 Arrowhead Pharmaceuticals Company Information
  15. 8.3.2 Arrowhead Pharmaceuticals Business Overview
  16. 8.3.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolio
  18. 8.3.5 Arrowhead Pharmaceuticals Recent Developments
  19. 8.4 Dicerna Pharmaceuticals
  20. 8.4.1 Dicerna Pharmaceuticals Company Information
  21. 8.4.2 Dicerna Pharmaceuticals Business Overview
  22. 8.4.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolio
  24. 8.4.5 Dicerna Pharmaceuticals Recent Developments
  25. 8.5 Ionis Pharmaceutical
  26. 8.5.1 Ionis Pharmaceutical Company Information
  27. 8.5.2 Ionis Pharmaceutical Business Overview
  28. 8.5.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ionis Pharmaceutical Vector-Based RNAi Product Portfolio
  30. 8.5.5 Ionis Pharmaceutical Recent Developments
  31. 8.6 Phio Pharmaceutical
  32. 8.6.1 Phio Pharmaceutical Company Information
  33. 8.6.2 Phio Pharmaceutical Business Overview
  34. 8.6.3 Phio Pharmaceutical Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Phio Pharmaceutical Vector-Based RNAi Product Portfolio
  36. 8.6.5 Phio Pharmaceutical Recent Developments
  37. 8.7 Qiagen NV
  38. 8.7.1 Qiagen NV Company Information
  39. 8.7.2 Qiagen NV Business Overview
  40. 8.7.3 Qiagen NV Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qiagen NV Vector-Based RNAi Product Portfolio
  42. 8.7.5 Qiagen NV Recent Developments
  43. 8.8 Quark Pharmaceuticals
  44. 8.8.1 Quark Pharmaceuticals Company Information
  45. 8.8.2 Quark Pharmaceuticals Business Overview
  46. 8.8.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Quark Pharmaceuticals Vector-Based RNAi Product Portfolio
  48. 8.8.5 Quark Pharmaceuticals Recent Developments
  49. 8.9 Silence Therapeutics
  50. 8.9.1 Silence Therapeutics Company Information
  51. 8.9.2 Silence Therapeutics Business Overview
  52. 8.9.3 Silence Therapeutics Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Silence Therapeutics Vector-Based RNAi Product Portfolio
  54. 8.9.5 Silence Therapeutics Recent Developments
  55. 8.10 Merck & Co.
  56. 8.10.1 Merck & Co. Company Information
  57. 8.10.2 Merck & Co. Business Overview
  58. 8.10.3 Merck & Co. Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co. Vector-Based RNAi Product Portfolio
  60. 8.10.5 Merck & Co. Recent Developments
  61. 8.11 Thermo Fisher Scientific
  62. 8.11.1 Thermo Fisher Scientific Company Information
  63. 8.11.2 Thermo Fisher Scientific Business Overview
  64. 8.11.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Thermo Fisher Scientific Vector-Based RNAi Product Portfolio
  66. 8.11.5 Thermo Fisher Scientific Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vector-Based RNAi Value Chain Analysis
  2. 9.1.1 Vector-Based RNAi Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vector-Based RNAi Production Mode & Process
  6. 9.2 Vector-Based RNAi Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vector-Based RNAi Distributors
  9. 9.2.3 Vector-Based RNAi Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst